SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LTK007 who wrote (43533)3/24/2002 5:25:42 PM
From: Jdaasoc  Read Replies (1) of 99280
 
An FDA advisory committee began considering whether to switch Claritin and similar nonsedating antihistamines, such as Aventis SA's Allegra and Pfizer Inc.'s Zyrtec, to nonprescription status.

Neighbor works for Scehering and was very clear that they decided that it was better to make Claritin an OTC drug before generics were made by competitors. I think Schering will decide to market it like premium brand like Bayer asprin and Tydenol. I asked her for the unpronounable generic name to see how it would sound after BJ's or Costco. I do not see a problem here maybe a advantage since there will be no insurance companies telling them how much they are willing to pay for it.
She has 2 children in high school and wonders how she is going to pay for college and retirement with her 401K plan in tatters. Only bitch she has about company is that it is run by accountants not medical researchers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News